Linked Life Data

10086794

Source:http://linkedlifedata.com/resource/pubmed/id/10086794

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
1999-4-15
pubmed:abstractText
AL amyloidosis patients ineligible for dose-intensive melphalan (200 mg/m2) were enrolled on a phase 11 trial to be treated with two cycles of intermediate-dose melphalan (IDM 100 mg/m2) and mobilized blood stem cells (BSC). For mobilization patients were randomized to either GM-CSF 250 microg/m2 for 3 d followed by G-CSF 10 microg/ kg for 3 d (GM+G), or G-CSF 10 microg/kg for 6 d (G-alone), with leukaphereses on days 5, 6 and 7. To minimize morbidity, we planned to support each cycle with 3 5 x 106 CD34+ cells/kg and had a collection target of 7 x 10(6) CD34+ cells/kg. Those who did not achieve the target were treated with one cycle of IDM. 30 patients, a median of 62 years old and 7 months from diagnosis, were enrolled. Both mobilization regimens were generally well tolerated, and similar in terms of CD34+ cells and CFU-GM collected, but only 6/28 patients achieved the collection target (GM+G four, G-alone two). Despite a 19% incidence of grade 4 toxicities, IDM therapy was well tolerated. At a median follow-up of 24 months (19-36) 57% of patients had survived, 17% with durable complete haematological responses and 40% with improved or stable amyloid organ involvement, including 3/9 patients with predominant cardiac amyloid who are alive 2-3 years after treatment. The 100 d mortality was 20%. In conclusion, no definitive differences were identified between the mobilization regimens and IDM was an active regimen in AL for selected patients.
pubmed:grant
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Mar
pubmed:issn
0007-1048
pubmed:author
pubmed:issnType
Print
pubmed:volume
104
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
553-9
pubmed:dateRevised
2007-11-14
pubmed:meshHeading
pubmed-meshheading:10086794-Adult, pubmed-meshheading:10086794-Aged, pubmed-meshheading:10086794-Amyloidosis, pubmed-meshheading:10086794-Antineoplastic Agents, Alkylating, pubmed-meshheading:10086794-Drug Combinations, pubmed-meshheading:10086794-Female, pubmed-meshheading:10086794-Granulocyte Colony-Stimulating Factor, pubmed-meshheading:10086794-Granulocyte-Macrophage Colony-Stimulating Factor, pubmed-meshheading:10086794-Hematopoietic Stem Cell Mobilization, pubmed-meshheading:10086794-Hematopoietic Stem Cell Transplantation, pubmed-meshheading:10086794-Humans, pubmed-meshheading:10086794-Infusions, Intravenous, pubmed-meshheading:10086794-Leukapheresis, pubmed-meshheading:10086794-Male, pubmed-meshheading:10086794-Melphalan, pubmed-meshheading:10086794-Middle Aged, pubmed-meshheading:10086794-Survival Analysis
pubmed:year
1999
pubmed:articleTitle
Intermediate-dose intravenous melphalan and blood stem cells mobilized with sequential GM+G-CSF or G-CSF alone to treat AL (amyloid light chain) amyloidosis.
pubmed:affiliation
Department of Medicine, Stem-cell Transplant Program, Boston Medical Center and Boston University School of Medicine, Massachusetts 02118, USA. raymond.comenzo@bmc.org
pubmed:publicationType
Journal Article, Clinical Trial, Research Support, U.S. Gov't, P.H.S., Randomized Controlled Trial, Research Support, Non-U.S. Gov't